Amil M Shah1, Patricia Campbell2, Gabriela Querejeta Rocha2, Andrew Peacock3, Robyn J Barst4, Debbie Quinn5, Scott D Solomon2. 1. Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, USA ashah11@partners.org. 2. Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, USA. 3. Scottish Pulmonary Vascular Unit, Regional Heart and Lung Centre, Glasgow, UK. 4. Division of Pediatric Cardiology, Columbia University College of Physicians and Surgeons, New York, NY, USA. 5. Novartis Pharmaceuticals, East Hanover, NJ, USA.
Abstract
AIMS: Imatinib mesylate, as add-on therapy in patients with pulmonary arterial hypertension (PAH) who remain inadequately treated despite receiving at least two PAH-specific drugs, improves exercise capacity and haemodynamics. We evaluated whether 24 weeks of add-on therapy with imatinib compared with placebo also improves right ventricular (RV) function assessed by echocardiography. METHODS AND RESULTS: Echocardiograms were obtained at baseline, 12 weeks, and 24 weeks in 74 patients randomized to imatinib or placebo in the Imatinib in Pulmonary arterial hypertension, a Randomized Efficacy Study (IMPRES) trial. Right ventricular function was assessed by tissue Doppler tricuspid annular peak systolic velocity (TA S'), tricuspid annular plane systolic excursion (TAPSE), RV Tei index, and RV fractional area change. Between-treatment-group differences in the changes from baseline to week-24 were assessed using an ANCOVA with the last observation carried forward. At week-24 patients randomized to imatinib demonstrated greater improvements in TA S' (1.6 ± 2.3 imatinib vs. 0.5 ± 2.4 cm/s placebo, P = 0.007) and RV Tei index (-0.11 ± 0.18 imatinib vs. 0.05 ± 0.18 placebo, P = 0.005) compared with placebo, but not in TAPSE (0.07 ± 0.44 imatinib vs. 0.03 ± 0.32 cm placebo, P = 0.08). Imatinib therapy was also associated with significant reduction in peak tricuspid regurgitation velocity, increase in LV size, and improvement in LV early diastolic relaxation velocity. CONCLUSIONS: Among patients with advanced PAH who remain symptomatic on at least two PAH-specific drugs, treatment withimatinib compared with placebo is associated with significant improvements in echocardiographic measures of RV function, in addition to LV size and LV early diastolic relaxation. CLINICAL TRIAL REGISTRATION: NCT00902174 (Clinicaltrials.gov). Published on behalf of the European Society of Cardiology. All rights reserved.
RCT Entities:
AIMS: Imatinib mesylate, as add-on therapy in patients with pulmonary arterial hypertension (PAH) who remain inadequately treated despite receiving at least two PAH-specific drugs, improves exercise capacity and haemodynamics. We evaluated whether 24 weeks of add-on therapy with imatinib compared with placebo also improves right ventricular (RV) function assessed by echocardiography. METHODS AND RESULTS: Echocardiograms were obtained at baseline, 12 weeks, and 24 weeks in 74 patients randomized to imatinib or placebo in the Imatinib in Pulmonary arterial hypertension, a Randomized Efficacy Study (IMPRES) trial. Right ventricular function was assessed by tissue Doppler tricuspid annular peak systolic velocity (TA S'), tricuspid annular plane systolic excursion (TAPSE), RV Tei index, and RV fractional area change. Between-treatment-group differences in the changes from baseline to week-24 were assessed using an ANCOVA with the last observation carried forward. At week-24 patients randomized to imatinib demonstrated greater improvements in TA S' (1.6 ± 2.3 imatinib vs. 0.5 ± 2.4 cm/s placebo, P = 0.007) and RV Tei index (-0.11 ± 0.18 imatinib vs. 0.05 ± 0.18 placebo, P = 0.005) compared with placebo, but not in TAPSE (0.07 ± 0.44 imatinib vs. 0.03 ± 0.32 cm placebo, P = 0.08). Imatinib therapy was also associated with significant reduction in peak tricuspid regurgitation velocity, increase in LV size, and improvement in LV early diastolic relaxation velocity. CONCLUSIONS: Among patients with advanced PAH who remain symptomatic on at least two PAH-specific drugs, treatment with imatinib compared with placebo is associated with significant improvements in echocardiographic measures of RV function, in addition to LV size and LV early diastolic relaxation. CLINICAL TRIAL REGISTRATION: NCT00902174 (Clinicaltrials.gov). Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Lawrence G Rudski; Wyman W Lai; Jonathan Afilalo; Lanqi Hua; Mark D Handschumacher; Krishnaswamy Chandrasekaran; Scott D Solomon; Eric K Louie; Nelson B Schiller Journal: J Am Soc Echocardiogr Date: 2010-07 Impact factor: 5.251
Authors: Raymond L Benza; Dave P Miller; Mardi Gomberg-Maitland; Robert P Frantz; Aimee J Foreman; Christopher S Coffey; Adaani Frost; Robyn J Barst; David B Badesch; C Gregory Elliott; Theodore G Liou; Michael D McGoon Journal: Circulation Date: 2010-06-28 Impact factor: 29.690
Authors: Ronald J Oudiz; Nazzareno Galiè; Horst Olschewski; Fernando Torres; Adaani Frost; Hossein A Ghofrani; David B Badesch; Michael D McGoon; Vallerie V McLaughlin; Ellen B Roecker; Brooke C Harrison; Darrin Despain; Christopher Dufton; Lewis J Rubin Journal: J Am Coll Cardiol Date: 2009-11-17 Impact factor: 24.094
Authors: Nagesh S Anavekar; Hicham Skali; Mikhail Bourgoun; Jalal K Ghali; Lars Kober; Aldo P Maggioni; John J V McMurray; Eric Velazquez; Robert Califf; Marc A Pfeffer; Scott D Solomon Journal: Am J Cardiol Date: 2008-03-01 Impact factor: 2.778
Authors: S Giusca; V Dambrauskaite; C Scheurwegs; J D'hooge; P Claus; L Herbots; M Magro; F Rademakers; B Meyns; M Delcroix; J-U Voigt Journal: Heart Date: 2009-08-30 Impact factor: 5.994
Authors: Gabriela Querejeta Roca; Patricia Campbell; Brian Claggett; Ali Vazir; Debbie Quinn; Scott D Solomon; Amil M Shah Journal: Eur J Heart Fail Date: 2014-11-04 Impact factor: 15.534
Authors: Gabriela Querejeta Roca; Patricia Campbell; Brian Claggett; Scott D Solomon; Amil M Shah Journal: Circ Cardiovasc Imaging Date: 2015-11 Impact factor: 7.792
Authors: Andrew M Bellinger; Carlos L Arteaga; Thomas Force; Benjamin D Humphreys; George D Demetri; Brian J Druker; Javid J Moslehi Journal: Circulation Date: 2015-12-08 Impact factor: 29.690
Authors: Young Lee; S Balakrishna Pai; Ravi V Bellamkonda; David H Thompson; Jaipal Singh Journal: J Pharmacol Exp Ther Date: 2018-04-25 Impact factor: 4.030